key: cord-0737978-4m9ngo8g
authors: Akiyama, Yutaka; Ishida, Takashi
title: Relationship between COVID-19 death toll doubling time and national BCG vaccination policy
date: 2020-04-17
journal: nan
DOI: 10.1101/2020.04.06.20055251
sha: c25c7c5d5c05d8ef0d66da0b2ddc4335c4884566
doc_id: 737978
cord_uid: 4m9ngo8g

In this manuscript, we showed a statistically significant difference of the doubling times of the death toll between the group of countries with national universal Bacillus Calmette-Guerin (BCG) vaccination and the group without it for recent years. Based on a statistical test, the distributions of the doubling time of these two groups were significantly different (p=0.007). Miller et al. reported the relationship between BCG vaccination and mortality for COVID-19 based on deaths per million inhabitants. However, they did not take into account the differences in COVID-19 detection rates among the countries and the epidemic stages of the countries. Therefore we used a doubling time of the death toll as a more stable indicator instead. We also investigated the dependency of the BCG strains. Among the 42 BCG-vaccinated countries, the median doubling time of the eight countries using "Tokyo 172-1" strain at least partially (Japan, Iraq, Malaysia, South Korea, Philippines, Saudi Arabia, Pakistan, and Bangladesh) was 7.2 days, and that of the other 34 vaccinated countries was 5.5 days. Their distributions were also significantly different (p=0.026).

account the differences in COVID-19 detection rates among the countries and the epidemic stages of the countries. Therefore we used a doubling time (DT) of the death toll as a more stable indicator.

First, we investigated the DT of COVID-19 deaths in 47 countries (source: Our World in Data, 3 as of 5 April 2020). We defined the baseline date of each country as the date when fatalities of at least five people was first observed in the country. We covered all countries that have at least 10-day observation period and had a population of more than 1 million. To exclude the effect of social interventions, the death toll data of the country was truncated by 30 days after the baseline date (for China, South Korea, Iran, Italy, Japan, and USA).

Next, we surveyed the national BCG vaccination policies of each country (sources: BCG Atlas, 4 WHO-UNICEF report, 5 and other 12 papers). The 47 countries were divided into two groups based on whether the majority of the population between the ages of 0 and 29 was vaccinated ("BCG") or not ("non-BCG"). BCG vaccination records are reliable only for the last 30 years for several countries. We also investigated the dependency of the BCG strains. Among the 32 "BCG" countries, the median DT of the four countries using "Tokyo 172-1" strain (Japan, Iraq, Malaysia, and Pakistan) was 6.8, and that of the other 28 vaccinated countries was 3.8. Their distributions were also significantly different at the significance level of 0.05 ( 0.024).

We showed a statistically significant difference of the doubling times of the death toll between "BCG" and "non-BCG" countries. The correlation might be a spurious and does not directly imply causality.

Data and full references used in the analysis are available at http://www.bi.cs.titech.ac.jp/COVID-19/Death_vs_BCGpolicy.html.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 17, 2020. . https://doi.org/10.1101/2020.04.06.20055251 doi: medRxiv preprint

Non-specific effects of BCG vaccine on viral infections

Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Total deaths, Coronavirus Source Data

A Database of Global BCG Vaccination Policies and Practices

WHO-UNICEF estimates of BCG coverage

Y.A. designed the study, and performed literature search, data collection, and basic data analysis. T.I. performed the statistical tests, and made a figure. Y.A. and T.I. wrote the manuscript.

None Ethics committee approval:CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2020. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 17, 2020. . https://doi.org/10.1101/2020.04.06.20055251 doi: medRxiv preprint